Skip to main content
OpenTrials
Completed

NCT Number: NCT04409561

Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

This is a single center, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally healthy adults representative of the US population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mercy Health St. Vincent

Toledo, Ohio, 43608, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, aged ≥ 18 years.
  • Apparently healthy as determined by a subject questionnaire.

Exclusion criteria

  • Current diagnosis, or history, of any underlying major medical condition determined by the investigator, including but not limited to:
  • Heart disease
  • Stroke
  • Renal disease
  • Liver disease
  • Pancreatic disease
  • Chronic obstructive pulmonary disorder
  • Bleeding disorders
  • Hypercalcitoninemia
  • HIV AIDS
  • Receiving antibiotic therapy
  • Suspected infection
  • Immunosuppression
  • Underwent procedures related to sepsis, or diagnosed with sepsis, within the last 12 months.
  • Current diagnosis of uncontrolled hypertension, hypotension, or diabetes.
  • Diagnosis of bacterial, fungal, or malaria infection within the last 3 months that required antimicrobial treatment.

5 )Experienced severe trauma, surgery, cardiac shock, or severe burn within the previous 3 months requiring medical care.

  • Current diagnosis of cancer within the last 12 months.
  • Received immunotherapy to stimulate or inhibit cytokines within the last 12 months.
  • Hospitalization for more than 24 hours within the last 3 months.
  • Reported as currently pregnant or nursing a child
  • Unable or unwilling to provide the required blood sample for testing.
  • Any other criteria that, in the opinion of the investigator, would render the participant unsuitable for inclusion in the trial.

Treatment and study plan

Blood collection

Device

9 mL K3-EDTA anticoagulated venous whole blood and 9 mL lithium heparin anticoagulated venous whole blood will be collected, processed in plasma and stored until the shipment to the sponsor for PSP measurement on the abioSCOPE device with IVD CAPSULE PSP kits

Primary outcomes

  1. Determination of reference range interval of PSP

    Time frame: Day 1

    To determine the reference range intervals of PSP values measured using abioSCOPE device with the PSP assay in a generally healthy population representative of the US population.

Secondary outcomes

  1. Collect medical data of healthy volunteer

    Time frame: Day 1

    To collect medical data from the 150 study participants using a volunteer questionnaire

  2. Obtain well characterised samples library to be used for future tests development

    Time frame: Day 1

    Whole blood collection from 150 healthy subject to be used for future tests development.

Sponsors and collaborators

Lead sponsor

Abionic SA

Industry

Collaborators

  • Boston Biomedical Associates
  • Ocean State Clinical Coordinating Center

Registry information

Official study title

A Study to Establish a Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

Important dates

Study start
2021
Primary completion
2021
Study completion
2022
First posted
Jun 1, 2020
Registry last updated
Mar 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.